# Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

Source: https://onco.cc/institutions/pascale-naples/  
OnCo record `pascale-naples` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Fondazione Pascale in Naples is the national cancer institute for southern Italy; Paolo Ascierto's unit was a lead investigator in the CheckMate and RELATIVITY melanoma trials, and Nicola Normanno's group is a reference for liquid biopsy in lung and colorectal cancer.

## Summary

The Fondazione Pascale is the IRCCS national cancer institute for southern Italy and one of the largest cancer hospitals in the country. Paolo Ascierto's melanoma, immunotherapy and innovative therapies unit has been a leading investigator in the CheckMate and RELATIVITY trials that established checkpoint blockade and the nivolumab-relatlimab combination in melanoma, and the institute hosts the Melanoma Bridge and Immunotherapy Bridge meetings. Nicola Normanno's molecular biology group is a reference for liquid biopsy and predictive biomarkers in lung and colorectal cancer. Clinical programmes span thoracic, gastrointestinal, breast, urological and head and neck oncology, radiotherapy and haematology, with a phase 1 unit and a Campania-wide oncology network role.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Pascale; INT Napoli; National Cancer Institute of Naples
- City: Naples, IT
- Type: cancer-center
- Website: https://www.istitutotumori.na.it

## Sources

- Homepage: https://www.istitutotumori.na.it
- Melanoma Bridge: https://www.melanomabridge.org

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/), [LAG-3](https://onco.cc/targets/lag3/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Relatlimab + nivolumab](https://onco.cc/drugs/relatlimab-nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- trials: [CheckMate 067](https://onco.cc/trials/checkmate-067/)
- people: [Maurizio Di Mauro](https://onco.cc/people/maurizio-di-mauro/), [Paolo A. Ascierto](https://onco.cc/people/paolo-ascierto/)
- institutions: [IRCCS Regina Elena National Cancer Institute](https://onco.cc/institutions/regina-elena-rome/)

---
JSON: https://onco.cc/api/v1/entities/pascale-naples.json